See referenced original article on pages 1695-1701, this issue.
Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma
Article first published online: 27 FEB 2014
© 2014 American Cancer Society
Volume 120, Issue 11, pages 1617–1619, 1 June 2014
How to Cite
Ascierto, P. A. and Margolin, K. (2014), Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. Cancer, 120: 1617–1619. doi: 10.1002/cncr.28622
- Issue published online: 20 MAY 2014
- Article first published online: 27 FEB 2014
- Manuscript Accepted: 13 DEC 2013
- Manuscript Received: 18 NOV 2013
The use of sequential therapy with ipilimumab and vemurafenib reported by Ackerman et al in this issue demonstrates that patients who failed BRAF inhibitor therapy appeared to have an inferior outcome than patients who received ipilimumab followed by BRAF inhibitor therapy. These results are in line with previous experience and provide additional evidence to support the use of ipilimumab before a BRAF inhibitor in the majority of patients with advanced melanoma who have an activating BRAF mutation and who are treated outside of a clinical trial.